The objective of HERACLES cohort A [146] was to examine the efficacy of dual HER2 blockade with trastuzumab plus lapatinib in patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) who exhibited HER2 amplifications and/or HER2 overexpression. Here, KRAS is linked to metastatic colorectal cancer.